CN101058607A - Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof - Google Patents
Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof Download PDFInfo
- Publication number
- CN101058607A CN101058607A CN 200610018839 CN200610018839A CN101058607A CN 101058607 A CN101058607 A CN 101058607A CN 200610018839 CN200610018839 CN 200610018839 CN 200610018839 A CN200610018839 A CN 200610018839A CN 101058607 A CN101058607 A CN 101058607A
- Authority
- CN
- China
- Prior art keywords
- cytotoxin
- helicobacter pylori
- thalline
- yolk antibody
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses an anti-pylorus screw thallus and chicken cytotoxin yolk antibody and application, which is characterized by the following: adopting pylorus screw thallus and cytotoxin form polyvalent antigen immune health hen; extracting anti-pylorus screw thallus and ytotoxin yolk antibody from yolk; fitting for treating relative disease infected by pylorus screw thallus.
Description
One, technical field
The present invention relates to a kind of product with antibody activity---anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody, and relate to its manufacturing process and application.
Two, technical background
Nineteen eighty-two, Australia's scholar's Barry Marshall and Luo Bin Warren have been found helicobacter pylori (Helicobacter pylori, therefore Hp), prove that this infectation of bacteria stomach can cause gastritis, stomach ulcer and duodenal ulcer, and obtained Nobel's physiology in 2005 and medical science prize.
The epidemiology survey data shows that the infection rate of Hp is about 40%～60% in the population of China.Because the living environment of Hp is special, medicine is difficult for arriving, so the difficulty of radical cure is very big.At present, triple therapy, quadruple chemotherapy are adopted in the infection of clinical treatment Hp more, promptly adopt microbiotic, antiviral drug and press down the medication combined use of acids.But these therapy medicine consumptions are big, and the time is long, and side reaction is strong, make the patient be difficult to stand, and resistance constantly increases, and curative effect worse and worse.Therefore, adopting the passive immunization protection is a new way of control helicobacter pylori infection.
Do not see in the prior art and use helicobacter pylori thalline and cytotoxin to form polyvalent antigen, immune health hen, the report of extraction anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody from the ovum that it produced again.
Three, summary of the invention
The invention provides a kind of product with antibody activity---anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody;
The invention provides above-mentioned preparation technology with antibody activity product;
The invention provides above-mentioned application approach: with above-mentioned product preparation biotechnological formulation with antibody activity, be used for the treatment of the relative disease that causes because of helicobacter pylori infection, be used for the prevention of helicobacter pylori infection with antibody activity product.
Provided by the present invention above-mentionedly have the antibody activity product and be characterised in that: the helicobacter pylori thalline is had antibody activity, helicobacter pylori cytotoxin is had antibody activity.Wherein helicobacter pylori cytotoxin comprises but does not include only vacuolating cytotoxin (VacA) and cytotoxin sample albumen (CagA).
Above-mentioned preparation technology with antibody activity product provided by the present invention is as follows:
1. prepare helicobacter pylori thalline and cytotoxin polyvalent antigen
Obtain producing cytotoxic helicobacter pylori bacterial classification from helicobacter pylori infection person lesions position isolation identification, the cytotoxin that is produced comprises but does not include only vacuolating cytotoxin (VacA) and cytotoxin sample albumen (CagA).
Above-mentioned bacterial classification inoculation was cultivated 72 hours in the brucella broth substratum, centrifugal thalline and the culture supernatant of collecting respectively, culture supernatant obtains cytotoxin by ultrafiltration and concentration.
Thalline is carried out sterilization, and cytotoxin carries out detoxification, after being mixed in proportion, adds isopyknic freund adjuvant, and the emulsification mixing obtains helicobacter pylori thalline and cytotoxin polyvalent antigen.
2. the immunity hen that lays eggs
Select the healthy hen isolated rearing of laying eggs for use, carry out the above-mentioned multivalence combined vaccines of chicken muscle multi-point injection, later on every two all booster immunizations once, immunity is three times altogether, begins to collect ovum gallinaceum after three weeks, and 4 ℃ store for future use.
3. extraction yolk antibody
Water dilution method is adopted in the extraction of above-mentioned anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody: separate yolk from the immune ovum gallinaceum of collecting, with the deionized water dilution, adjust proper pH value, 4 ℃ left standstill 8 hours or spent the night, the centrifuging and taking supernatant concentrates, and lyophilize obtains above-mentioned chicken yolk antibody.
Provided by the present invention above-mentioned to have the antibody activity product be to get by helicobacter pylori thalline and the cytotoxin immunity hen that lays eggs, and has specificity, and the relative disease that the control helicobacter pylori infection is caused has good effect.The present invention adopts hen lay eggs to be carrier, and safety non-toxic is easy to industrialization.
Four, embodiment
Embodiment one
Anti-helicobacter pylori thalline and cytotoxin egg yolk antibody product with antibody activity can obtain by following steps: the polyvalent antigen that preparation helicobacter pylori thalline and cytotoxin are formed, with this polyvalent antigen immune health hen, collect it then and lay eggs, from it is laid eggs, extract anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody again.
Embodiment two
The preparation of bacterial classification: separate the helicobacter pylorus bacteria strain from helicobacter pylori infection person lesions position, adopt the strain identification system to identify, obtain producing cytotoxic bacterial classification, the cytotoxin that is produced comprises but does not include only vacuolating cytotoxin (VacA) and cytotoxin sample albumen (CagA).
Embodiment three
Helicobacter pylori thalline and the preparation of cytotoxin polyvalent antigen: above-mentioned bacterial classification inoculation was cultivated 72 hours in the brucella broth substratum, centrifugal thalline and the culture supernatant of collecting respectively, culture supernatant obtains cytotoxin by ultrafiltration and concentration.Thalline is carried out sterilization, and cytotoxin carries out detoxification, after being mixed in proportion, adds isopyknic freund adjuvant, and the emulsification mixing obtains helicobacter pylori thalline and cytotoxin polyvalent antigen.
Embodiment four
The immunity hen that lays eggs: select the healthy hen isolated rearing of laying eggs for use, carry out the above-mentioned polyvalent antigen of chicken muscle multi-point injection, later on every two all booster immunizations once, immunity is three times altogether, begins to collect ovum gallinaceum after three weeks, and 4 ℃ store for future use.
Embodiment five
Water dilution method is adopted in the extraction of above-mentioned anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody: separate yolk from the immune ovum gallinaceum of collecting, with the deionized water dilution, adjust proper pH value, 4 ℃ left standstill 8 hours or spent the night, the centrifuging and taking supernatant concentrates, and lyophilize obtains above-mentioned chicken yolk antibody.
Embodiment six
Will be by the anti-helicobacter pylori thalline and the cytotoxin chicken yolk antibody of method for preparing, mix according to a certain percentage with corresponding auxiliary material, make oral liquid, granule, tablet or capsule, be used for the treatment of because of diseases such as chronic gastritis that helicobacter pylori infection causes, duodenal ulcers; Also can be used to prevent helicobacter pylori infection.
Embodiment seven
To as foodstuff additive, add in the food by the anti-helicobacter pylori thalline and the cytotoxin chicken yolk antibody of method for preparing, make food, be used to prevent helicobacter pylori infection with nourishing function.
Claims (5)
1. the product with antibody activity---anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody.It is characterized in that: the helicobacter pylori thalline is had antibody activity, helicobacter pylori cytotoxin is had antibody activity.Wherein helicobacter pylori cytotoxin comprises but does not include only vacuolating cytotoxin (VacA) and cytotoxin sample albumen (CagA).
2. anti-helicobacter pylori thalline according to claim 1 and cytotoxin egg yolk antibody product, can obtain from following steps: the polyvalent antigen that preparation helicobacter pylori thalline and cytotoxin are formed, with this vaccine immunity healthy hens, collect it then and lay eggs, from it is laid eggs, extract anti-helicobacter pylori thalline and cytotoxin chicken yolk antibody again.
3. according to claim 1,2 described anti-helicobacter pylori thalline and cytotoxin egg yolk antibody products, it is characterized in that: the polyvalent antigen that preparation helicobacter pylori thalline and cytotoxin are formed, wherein helicobacter pylori cytotoxin comprises but does not include only vacuolating cytotoxin (VacA) and cytotoxin sample albumen (CagA), with this polyvalent antigen immune health hen.Helicobacter pylori thalline and the preparation of cytotoxin polyvalent antigen: above-mentioned bacterial classification inoculation was cultivated 72 hours in the brucella broth substratum, centrifugal thalline and the culture supernatant of collecting respectively, culture supernatant obtains cytotoxin by ultrafiltration and concentration.Thalline is carried out sterilization, and cytotoxin carries out detoxification, after being mixed in proportion, adds isopyknic freund adjuvant, and the emulsification mixing obtains helicobacter pylori thalline and cytotoxin polyvalent antigen.
4. according to claim 1,2,3 described anti-helicobacter pylori thalline and cytotoxin egg yolk antibody products, be used for the treatment of application in the medicine of the relative disease that causes because of helicobacter pylori infection in preparation.
5. according to claim 1,2,3 described anti-helicobacter pylori thalline and cytotoxin egg yolk antibody products, be used for preventing the application of the healthcare products of helicobacter pylori infection in preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610018839 CN101058607A (en) | 2006-04-20 | 2006-04-20 | Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610018839 CN101058607A (en) | 2006-04-20 | 2006-04-20 | Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101058607A true CN101058607A (en) | 2007-10-24 |
Family
ID=38864924
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610018839 Pending CN101058607A (en) | 2006-04-20 | 2006-04-20 | Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101058607A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961704A (en) * | 2014-04-25 | 2014-08-06 | 深圳雅臣生物科技有限公司 | Preparation method and preparation agent of nano lipidosome compound IgY resisting Helicobacter pylori, Pylori bacteria as well as related enzymes and adhesin of Helicobacter pylori and Pylori bacteria |
| CN109251247A (en) * | 2018-08-31 | 2019-01-22 | 菏泽睿智科技开发有限公司 | A kind of extracting method of helicobacter pylori Yolk antibody |
| CN111205367A (en) * | 2020-02-23 | 2020-05-29 | 珠海华敏医药科技有限公司 | Helicobacter pylori yolk antibody freeze-dried powder, preparation method and application preparation |
-
2006
- 2006-04-20 CN CN 200610018839 patent/CN101058607A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103961704A (en) * | 2014-04-25 | 2014-08-06 | 深圳雅臣生物科技有限公司 | Preparation method and preparation agent of nano lipidosome compound IgY resisting Helicobacter pylori, Pylori bacteria as well as related enzymes and adhesin of Helicobacter pylori and Pylori bacteria |
| CN109251247A (en) * | 2018-08-31 | 2019-01-22 | 菏泽睿智科技开发有限公司 | A kind of extracting method of helicobacter pylori Yolk antibody |
| CN111205367A (en) * | 2020-02-23 | 2020-05-29 | 珠海华敏医药科技有限公司 | Helicobacter pylori yolk antibody freeze-dried powder, preparation method and application preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1694954A (en) | Selection and use of lactic acid bacteria for reducing inflammmation caused by helicobacter | |
| CN108135992A (en) | Immunogenic fusion proteins | |
| CN1283663C (en) | Antithemolytic streptococcus, staphylococcus and candida albicans lgG antibody and preparation thereof | |
| WO2010063693A1 (en) | Process for production of vaccines | |
| CN101058607A (en) | Anti-helicobacter pylori thallus, cell toxin egg yolk antibody product, preparation and application thereof | |
| CN102743751A (en) | Preparation method of newcastle diseases, infectious bursal disease bigeminy high immunity-yolk-antibody lyophilized powder | |
| CN1206243C (en) | Yolk antibody and antigen of pig's infective enterogastritis virus and its preparing process | |
| CN102167726A (en) | Method for separating and extracting active polypeptide and immune ribonucleic acid by utilizing blood and spleen of animal | |
| CN102140430A (en) | Mouse-typhus salmonella gene-deletion mutant strain without containing resistance marks, vaccine and application thereof | |
| CN1594362A (en) | Yolk antibody specific for helicobacter pylori and its preparation and application | |
| CN1634989A (en) | Bacillus coli resisting chicken yolk antibody, its preparation and use | |
| KR100483369B1 (en) | Pediococcus pentosaceus CBT-8 which produces antimicrobial materials for restraining Helicobacter pylori and Listeria monocytogenes, and Production method of antimicrobial materials from Pediococcus pentosaceus CBT-8, and Application process for functional foods and/or drugs using the strain and the antimicrobial materials | |
| CN101074260A (en) | Production of hygrophilous monospermous bacterium main-protective antigen univalent and multivalent vitelline antibody and use in aquatic animal | |
| KR20190139583A (en) | A vaccine composition comprising recombinant protein of attenuated staphylococcal enterotoxin and cytotoxin | |
| KR100267746B1 (en) | Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli | |
| CN104511008A (en) | Preparation method of brain protein hydrolysate | |
| CN1354187A (en) | Hen egg yolk antibody for resisting pyloric helicobacterium cytotoxin, its preparation and application | |
| CN105497885B (en) | A kind of subunit vaccine and its preparation method and application | |
| CN1384119A (en) | Composite yolk antibody for resisting fowl's viral blight and its prepn and application | |
| CN113116938A (en) | Quadruple viable bacteria preparation and application thereof | |
| CN103721254A (en) | Method for preparing swine A-type clostridium perfringens aluminum hydroxide inactivated vaccine | |
| CN1385442A (en) | Compound yolk antibody capable of resisting fowl bacterial blight and its preparation and use | |
| KR102376876B1 (en) | Non-toxic Clostridium difficile toxin protein-fragments and uses thereof | |
| CN102908610B (en) | Propolis combination used for livestock and preparation method of same | |
| KR102196572B1 (en) | Composition for Fish Vaccine Containing Alginate Capsule and Preparing Method Thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C57 | Notification of unclear or unknown address | ||
| DD01 | Delivery of document by public notice |
Addressee: Lin Gang Document name: Notification before expiration of term |
|
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |